J&J Concerta, Methylphenidate Adverse Events Not New Signal, Committee Says

FDA's pediatric committee is hesitant to recommend a labeling change for attention deficit/hyperactivity disorder drugs based on current data. FDA should, however, communicate concerns about psychiatric events to the public, possibly through Drug Watch website.